Your session is about to expire
← Back to Search
Radiation Therapy
Re-irradiation for Brain Tumor
N/A
Recruiting
Led By Douglas Strother, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
The patient has a Lansky score of 40% or higher
The patient has a life expectancy anticipated to be at least 8 weeks with treatment using re-irradiation, with or without dexamethasone
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to three years from initial diagnosis of dipg
Awards & highlights
Study Summary
This trial will test whether re-irradiation can help treat DIPG, a type of brain tumor.
Who is the study for?
This trial is for individuals with a brain tumor called DIPG that's come back or gotten worse. They should be off cancer treatments for 14 days, have no uncontrolled medical issues, and not be pregnant. Participants must agree to avoid other trials, use birth control if needed, and report all medications taken during the study.Check my eligibility
What is being tested?
The study tests re-irradiation as a treatment for DIPG after it has progressed or recurred. It's a single-arm trial where everyone gets the same therapy without being compared to another group or receiving a placebo.See study design
What are the potential side effects?
While specific side effects are not listed here, re-irradiation may include risks such as skin irritation at the treatment site, fatigue, headaches, nausea, and potential late effects due to additional radiation exposure.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can carry out most of my daily activities on my own.
Select...
My doctor expects me to live at least 8 weeks with my upcoming treatment.
Select...
It has been over 180 days since my last radiation therapy for brain cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to three years from initial diagnosis of dipg
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to three years from initial diagnosis of dipg
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
second progression-free survival
Secondary outcome measures
overall survival
Trial Design
1Treatment groups
Experimental Treatment
Group I: Patients receiving re-irradiationExperimental Treatment1 Intervention
Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
792 Previous Clinical Trials
869,127 Total Patients Enrolled
2 Trials studying Diffuse Intrinsic Pontine Glioma
93 Patients Enrolled for Diffuse Intrinsic Pontine Glioma
Douglas Strother, MDPrincipal InvestigatorUniversity of Calgary
Lucie Lafay-Cousin, MDPrincipal InvestigatorUniversity of Calgary
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am eligible for treatment at this facility according to its policy.I agree to use effective birth control during my treatment.I am not pregnant, as the treatment could harm a developing fetus.It has been over 180 days since my last radiation therapy for brain cancer.I have recovered from all side effects of my previous cancer treatments.My doctor expects me to live at least 8 weeks with my upcoming treatment.I can carry out most of my daily activities on my own.I don't have any health issues that would affect my treatment.I agree to report all medications and therapies I use during and after ReRAD therapy.I haven't had any cancer treatment for the last 14 days.I have had radiation therapy before, but the total dose was less than 60 Gy.I am being treated at a location approved for this study.I cannot undergo the specific radiation therapy outlined in this study.
Research Study Groups:
This trial has the following groups:- Group 1: Patients receiving re-irradiation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are enrollees still being accepted into this trial?
"The research, which was originally posted on April 15th 2017 and revised recently in December 2021 is presently enrolling participants. This information can be found at clinicaltrials.gov."
Answered by AI
Are there considerable establishments running this experiment in the city at present?
"Apart from Stollery Children's Hospital in Edmonton, Alberta, BC Children's Hospital in Vancouver, British Columbia and Alberta Children's Hospital in Calgary, Ontario there are 12 other locations accepting patients for this trial."
Answered by AI
How many individuals are actively engaged in this trial?
"Affirmative. Clinicaltrials.gov attests that this clinical trial, initiated on April 15th 2017 and revised December 14th 2021, is currently recruiting participants. 27 people are needed by the research team from a dozen sites."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger